Astro Pak Acquires Purepass in High-Purity Systems Push

Astro Pak LLC, the Los Angeles–based precision cleaning and surface treatment specialist, has acquired Purepass Services Inc., a Tennessee firm specializing in passivation and electropolishing for semiconductor and pharmaceutical applications. The deal, announced June 3, positions Astro Pak to capture more of the rapidly growing demand for ultra-high-purity fluid systems as U.S. semiconductor fabrication expands and biopharma cleanroom standards tighten.

Financial terms weren't disclosed. But the acquisition marks Astro Pak's latest move to consolidate a fragmented market for specialized industrial cleaning services — a sector that's seen steady M&A activity as buyers chase recurring revenue from critical infrastructure maintenance contracts.

Purepass, based in Germantown, Tennessee, brings two decades of experience in passivation — the chemical treatment that forms a protective oxide layer on stainless steel to prevent corrosion in high-purity environments. The company also performs electropolishing, orbital welding, and cleanroom-grade piping installation for clients in semiconductors, pharmaceuticals, and biotechnology. Its customer base skews heavily toward fabs and pharma manufacturers operating under strict FDA and ISO cleanroom classifications.

"This isn't just about adding headcount," said Tom Speth, Astro Pak's CEO, in the announcement. "Purepass has built deep technical relationships in markets where precision isn't negotiable. We're talking about systems where a single particle can ruin a wafer lot or contaminate a biologic batch. That expertise doesn't scale through price competition — it scales through trust and technical depth."

The timing isn't accidental. U.S. semiconductor manufacturing is undergoing its largest expansion in decades, fueled by $52 billion in federal CHIPS Act subsidies and corporate commitments from Intel, TSMC, Samsung, and Micron to build or expand domestic fabs. Each new fabrication facility requires miles of ultra-high-purity piping to handle deionized water, specialty gases, and process chemicals — all of which demand passivated stainless steel to meet Class 10 and Class 100 cleanroom standards.

Passivation is non-negotiable in these environments. Without it, stainless steel surfaces shed microscopic iron particles that contaminate process fluids. In semiconductor fabs, where feature sizes have shrunk below 5 nanometers, even trace contamination can crater yields. The same holds in pharmaceutical fill-finish operations, where biologics are exposed to piping surfaces during sterile processing.

Market researcher ReportLinker projects the global semiconductor equipment services market — which includes cleanroom maintenance and surface treatment — will grow at a 7.2% compound annual rate through 2030, reaching $28 billion. Passivation and electropolishing services, while niche, are bundled into nearly every new fab buildout and retrofitted into aging facilities as cleanroom standards evolve.

Astro Pak has serviced aerospace, defense, and energy sectors for decades, cleaning rocket fuel tanks, nuclear reactor components, and oil refinery piping. But semiconductors and pharma represent higher-margin recurring work tied to operational uptime rather than episodic project cycles. Purepass's existing contracts give Astro Pak a foothold in facilities where service relationships can last years and switching costs are high.

Purepass generated an estimated $8-12 million in annual revenue prior to the acquisition, according to industry sources familiar with the company's operations. (Neither Astro Pak nor Purepass confirmed figures.) More valuable than the top line: Purepass holds cleanroom service contracts with multiple Fortune 500 semiconductor and pharmaceutical clients, relationships that took years to establish and involve strict vendor qualification processes.

The company's technical capabilities extend beyond standard passivation. Purepass performs electropolishing — an electrochemical process that removes surface material to create mirror-smooth finishes with minimal surface roughness (typically below 15 microinches Ra). This is critical in pharmaceutical applications where rough surfaces harbor bacteria and in semiconductor gas delivery systems where surface imperfections create particle traps.

Purepass also operates mobile cleanroom equipment, allowing it to perform on-site passivation and welding inside active manufacturing facilities without full shutdowns. For pharma clients operating under continuous manufacturing models or fabs running 24/7 production schedules, this capability minimizes costly downtime.

Astro Pak plans to retain Purepass's Tennessee operations and existing management team, according to the announcement. The company will continue operating under the Purepass name in the near term while integrating back-office functions and cross-training technicians on Astro Pak's broader service portfolio.

Purepass's Tennessee base sits within a two-hour radius of pharmaceutical manufacturing clusters in the Southeast and within reach of emerging semiconductor projects. Intel's planned Ohio fab complex, Micron's New York facility, and Samsung's Texas expansion all lie within Purepass's extended service area. Meanwhile, Astro Pak's existing West Coast facilities — concentrated in California and Arizona — already serve TSMC's Phoenix operations and legacy semiconductor fabs in Silicon Valley.

This isn't Astro Pak's first rodeo. The company has pursued a steady acquisition strategy over the past decade, absorbing regional cleaning and surface treatment firms to expand its geographic reach and technical capabilities. Previous deals included acquisitions of specialty cleaning providers serving aerospace (rocket engine component cleaning), defense (naval reactor systems), and oil and gas (refinery turnaround services).

The Purepass deal follows a familiar pattern: acquire a profitable, founder-led business with sticky customer relationships in a niche technical market, then cross-sell Astro Pak's broader service suite. In this case, that means introducing Purepass clients to Astro Pak's chemical cleaning, precision coating, and analytical testing services — offerings that often complement passivation work in the same facilities.

Astro Pak itself is backed by private equity. The company was acquired by Clearlake Capital Group in 2018, which has since supported additional bolt-on acquisitions to build out a national platform. Clearlake's thesis: industrial services tied to regulated, high-consequence environments (aerospace, defense, pharma, semiconductors) generate durable cash flows and benefit from vendor consolidation as customers prefer fewer, more capable partners over fragmented local providers.

The strategy has precedent. Similar roll-ups have played out in adjacent industrial service verticals — think Blackstone's consolidation of boiler and HVAC services or KKR's build-out of environmental remediation platforms. The common thread: acquiring technical expertise that can't be easily commoditized, then layering on operational scale and cross-selling.

What makes the cleanroom services market particularly attractive for this playbook is the qualification burden. Once a vendor is approved to work inside a Class 10 cleanroom or a pharmaceutical aseptic suite, switching costs are high. Re-qualifying a new provider requires audits, documentation reviews, and trial periods that can stretch months. That creates natural customer stickiness — exactly what PE buyers prize.

Astro Pak likely paid somewhere in the 6-8x EBITDA range for Purepass, based on comparable transactions in the industrial services sector. (Again, terms weren't disclosed, but this is standard for specialty service businesses with recurring revenue and strong customer concentration in regulated verticals.) If Purepass was generating $1.5-2 million in EBITDA, that implies a $9-16 million valuation — modest enough to generate returns through modest revenue synergies and margin improvement.

The upside comes from cross-selling and contract expansion. A client using Purepass for passivation might also need Astro Pak's precision coating services, analytical testing (to verify cleanliness levels), or ongoing maintenance contracts. Each incremental service attached to an existing customer relationship drops nearly pure margin to the bottom line.

The broader market context matters. U.S. semiconductor capital spending hit $50 billion in 2025, according to SEMI, the industry trade group — a figure that's projected to rise as CHIPS Act–funded facilities break ground. Each new fab requires not just initial cleanroom construction but ongoing maintenance as process tools and fluid systems age.

Passivation is typically required every 1-3 years in active semiconductor facilities as piping systems degrade from exposure to corrosive chemicals. In pharmaceutical environments, passivation frequency depends on cleaning protocols and product changeovers but averages every 18-24 months. That creates a recurring revenue stream tied to facility uptime rather than discretionary capex budgets.

The same dynamics are playing out in pharmaceutical manufacturing, where the shift toward biologics and continuous manufacturing has driven investments in new cleanroom capacity. Biologics — therapeutic proteins, monoclonal antibodies, cell and gene therapies — are far more sensitive to contamination than traditional small-molecule drugs. That's pushed pharmaceutical manufacturers to upgrade fluid handling systems and tighten surface finish specifications, both of which increase demand for electropolishing and passivation services.

Market research firm Grand View Research estimates the global pharmaceutical cleanroom technology market will reach $8.6 billion by 2030, growing at a 6.8% CAGR. Passivation and surface treatment services are a slice of that, but a high-margin one given the technical expertise required.

There's another angle here: skilled labor scarcity. Passivation technicians need training in chemistry, surface science, and cleanroom protocols — a combination that's not easy to hire off the street. Certified orbital welders, similarly, are in short supply as fab construction ramps. By acquiring Purepass, Astro Pak gains not just customer contracts but a trained workforce that can be deployed across a broader geography.

That matters more as labor costs climb. Industrial service providers are increasingly competing with construction trades and manufacturing operators for the same pool of technically skilled workers. Having an established team in place — rather than trying to recruit and train from scratch — shortens the path to capturing new contracts.

Astro Pak competes with a mix of regional specialty cleaning firms and divisions of larger industrial service conglomerates. Key competitors include Triverus Consulting (pharma cleanroom validation), Thermal Spray Technologies (aerospace and energy cleaning), and various smaller regional players offering passivation and electropolishing.

None have consolidated the market to the extent Astro Pak is attempting. Most remain regionally focused, family-owned, or subscale. That fragmentation creates ongoing M&A opportunities — but also means Astro Pak is racing to lock up vendor relationships before competitors (or new PE entrants) pursue the same playbook.

One thing to watch: whether other private equity firms start targeting the cleanroom services space more aggressively. If they do, valuation multiples for companies like Purepass could climb, making future bolt-ons more expensive and pressuring Astro Pak to move quickly on additional deals.

While Astro Pak doesn't disclose financials (it's private), a few proxies suggest how the combined entity might perform:

Customer concentration: How many of Purepass's top 10 clients overlap with Astro Pak's existing accounts? High overlap suggests faster cross-selling; low overlap means expanded market access but longer sales cycles.

Contract structure: Are Purepass's pharma and semiconductor contracts time-and-materials or fixed-price? The former offers more margin flexibility but less revenue predictability.

Technician utilization: Industrial service businesses live and die by billable hours. If Astro Pak can increase Purepass technician utilization by even 5-10 percentage points through better scheduling and route density, that flows straight to EBITDA.

The Purepass acquisition signals that cleanroom maintenance is shifting from a fragmented cottage industry to a consolidating platform market. As semiconductor and pharmaceutical clients demand more comprehensive vendor partnerships — single points of contact for cleaning, passivation, coating, and testing — smaller regional players face pressure to either scale up or sell out.

For Purepass's management team and employees, the deal likely offers access to Astro Pak's capital base, broader service portfolio, and national footprint. For customers, it means their passivation provider can now also handle precision cleaning, surface analysis, and coating work that previously required separate vendors.

The risk? Integration execution. Cleanroom service quality is deeply personal — it depends on individual technician skill, site-specific knowledge, and trust built over years. If key Purepass personnel leave or customer relationships fracture during the transition, the acquisition's value erodes quickly. Astro Pak's decision to retain Purepass's brand and management suggests awareness of this risk, but the proof will come in renewal rates and service quality metrics over the next 18-24 months.

Longer term, the deal reflects a bet that U.S. semiconductor and pharmaceutical manufacturing will continue growing faster than the supply of qualified cleanroom service providers. If that thesis holds — and if CHIPS Act subsidies translate into sustained domestic fab construction — Astro Pak will have positioned itself early in a multi-year infrastructure buildout. If fab projects stall or pharmaceutical capex cycles turn, the company will be left with higher overhead and underutilized capacity. That's the tension underlying every industrial services roll-up: you're buying future demand, not just current cash flow.